Camlin Fine Sciences Limited has secured 95.41% of the share capital in Vinpai following the conclusion of a simplified cash tender offer. The company now holds 4,351,894 shares and 4,325,158 theoretical voting rights in the French entity. Despite reaching this majority stake, Camlin Fine Sciences confirmed it will not request the Autorité des marchés financiers (AMF) to implement a squeeze-out procedure for Vinpai shares from the Euronext Growth Paris market.

The simplified cash tender offer, known as the offre publique d’achat simplifiée (OPAS), closed on July 6, 2026. The results of the offer were published by the AMF. The transaction targeted the remaining shares of Vinpai that were not already held by Camlin Fine Sciences.

Post-Offer Ownership Structure

The acquisition significantly increased Camlin Fine Sciences' control over Vinpai. The final ownership figures include 26,736 treasury shares treated as held by Camlin Fine Sciences in accordance with article L. 233-9, I, 2° of the French commercial code.

The calculation of theoretical voting rights is based on a total of 4,728,855 rights, in accordance with article 223-11, al 2 of the general regulation of the AMF.

Strategic Decision on Delisting

Camlin Fine Sciences referenced a previous press release dated March 16, 2026, regarding its decision not to pursue a squeeze-out. This means minority shareholders will retain their listing on the Euronext Growth Paris market, and the company will not force the buyout of remaining shares.

Advisors for the transaction included ALLinvest Securities as the presenting institution and FONTAINE AVOCATS as the legal advisor.

Camlin Fine Sciences Limited has accepted the resignation of Mr. Anvarhusen Bilakhiya from the position of Vice President - Principal Scientist (R&D), effective July 7, 2026. The resignation was tendered due to personal commitments, and the official was relieved from his duties at the close of business hours on the same day. This change impacts the company's senior management personnel structure within its research and development division.

The disclosure was made in compliance with Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, regarding the submission of the necessary details.

Mr. Bilakhiya was designated as a Senior Management Personnel of the company via a letter dated April 8, 2026. His resignation marks the cessation of his tenure with the company effective from the specified date in July 2026. The company has confirmed that the resignation was accepted and processed as per the regulatory norms.

The following table summarizes the key details of the management change:

The information regarding this change has been made available on the company's official website. The resignation letter submitted by Mr. Bilakhiya cited his desire to reside with his family in Vadodara as the primary reason for stepping down from his role.